Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cipla
Deloitte
Fish and Richardson
Fuji
Dow
Queensland Health
US Department of Justice
Moodys

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,452,162

« Back to Dashboard

Which drugs does patent 9,452,162 protect, and when does it expire?

Patent 9,452,162 protects ONIVYDE and is included in one NDA.

This patent has twenty-two patent family members in twenty-one countries.
Summary for Patent: 9,452,162
Title:Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Inventor(s): Bayever; Eliel (New York, NY), Dhindsa; Navreet (Boston, MA), Fitzgerald; Jonathan Basil (Cambridge, MA), Laivins; Peter (Rowayton, CT), Moyo; Victor (Concord, MA), Niyikiza; Clet (Gulph Mills, PA), Kim; Jaeyeon (Lexington, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/406,776
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,452,162

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,452,162

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,492,442 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Try a Free Trial
9,717,724 Methods for treating pancreatic cancer using combination therapies ➤ Try a Free Trial
9,339,497 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Try a Free Trial
9,364,473 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,452,162

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013202947 ➤ Try a Free Trial
Australia 2013274287 ➤ Try a Free Trial
Brazil 112014031088 ➤ Try a Free Trial
Canada 2875824 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Queensland Health
Express Scripts
Cipla
Cantor Fitzgerald
McKesson
Johnson and Johnson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.